
## Arianna Sartori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4558834/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. Multiple Sclerosis Journal, 2022, 28, 93-101.	3.0	13
2	A realâ€world study of alemtuzumab in a cohort of Italian patients. European Journal of Neurology, 2022, 29, 257-266.	3.3	15
3	Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes. Multiple Sclerosis and Related Disorders, 2022, 57, 103357.	2.0	4
4	Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. Multiple Sclerosis and Related Disorders, 2022, 58, 103424.	2.0	25
5	Paraneoplastic neurological syndromes associated with non-Hodgkin lymphoma: a case series. Neurological Sciences, 2022, 43, 2077-2079.	1.9	0
6	Isolated aphasic status epilepticus: CT perfusion, SPECT and EEG reveal neurovascular coupling and support the differential diagnosis. Epileptic Disorders, 2022, 24, 549-554.	1.3	2
7	Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillainâ€Barré syndrome and polyneuritis cranialis in COVIDâ€19 patients: A case series. Journal of Medical Virology, 2021, 93, 766-774.	5.0	74
8	Hiccups, severe vomiting and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies. Journal of Neuroimmunology, 2021, 352, 577488.	2.3	5
9	Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience. Neurological Sciences, 2021, 42, 5037-5043.	1.9	2
10	ASL MRI and 18F-FDG-PET in autoimmune limbic encephalitis: clues from two paradigmatic cases. Neurological Sciences, 2021, 42, 3423-3425.	1.9	12
11	<scp><sup>123</sup>lâ€Metaiodobenzylguanidine</scp> Myocardial Scintigraphy in Discriminating Degenerative Parkinsonisms. Movement Disorders Clinical Practice, 2021, 8, 717-724.	1.5	3
12	Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVIDâ€19 neuropathy patients. Journal of Medical Virology, 2021, 93, 5432-5437.	5.0	15
13	Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review. Journal of Neuroimmunology, 2021, 356, 577586.	2.3	15
14	Unveiling the relationship between autonomic involvement, fatigue, and cognitive dysfunction in early relapsing–remitting multiple sclerosis. Neurological Sciences, 2021, 42, 4281-4287.	1.9	3
15	Comfortable walking speed and energy cost of locomotion in patients with multiple sclerosis. European Journal of Applied Physiology, 2020, 120, 551-566.	2.5	18
16	Prevalence of hypohydration and its association with stroke severity and independence outcomes in acute ischemic stroke patients. Journal of Clinical Neuroscience, 2020, 72, 281-286.	1.5	10
17	Comment on "Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19― Seizure: the Journal of the British Epilepsy Association, 2020, 81, 166.	2.0	0
18	Effects of a cooling vest with sham condition on walking capacity in heat-sensitive people with Multiple Sclerosis. European Journal of Applied Physiology, 2020, 120, 2467-2476.	2.5	8

ARIANNA SARTORI

#	Article	IF	CITATIONS
19	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. Multiple Sclerosis and Related Disorders, 2020, 42, 102059.	2.0	4
20	Early putamen hypertrophy and ongoing hippocampus atrophy predict cognitive performance in the first ten years of relapsing-remitting multiple sclerosis. Neurological Sciences, 2020, 41, 2893-2904.	1.9	8
21	Efficacy of rituximab on seizure control and cognitive symptoms in leucineâ€rich, gliomaâ€inactivated 1 (LGI1) limbic encephalitis: a highâ€density electroencephalography case study. Epileptic Disorders, 2020, 22, 678-682.	1.3	6
22	Determinants of therapy switch in multiple sclerosis treatment-naÃ⁻ve patients: A real-life study. Multiple Sclerosis Journal, 2019, 25, 1263-1272.	3.0	36
23	Thrombolysis' benefits on early post-stroke language recovery in aphasia patients. Journal of Clinical Neuroscience, 2019, 70, 92-95.	1.5	7
24	Predictors of diagnostic delay in amyotrophic lateral sclerosis: a cohort study based on administrative and electronic medical records data. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 176-185.	1.7	34
25	Acute isolated aphasia as a challenging symptom in the emergency setting: Predictors of epileptic mimic versus ischemic stroke. Journal of Clinical Neuroscience, 2019, 67, 129-133.	1.5	4
26	Motor neuron disease as a treatment responsive paraneoplastic neurological syndrome in patient with small cell lung cancer, anti-Hu antibodies and limbic encephalitis. Journal of the Neurological Sciences, 2019, 400, 158-159.	0.6	6
27	Epidemiology of amyotrophic lateral sclerosis in Friuli-Venezia Giulia, North-Eastern Italy, 2002–2014: a retrospective population-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 90-99.	1.7	35
28	Early Recovery of Aphasia through Thrombolysis: The Significance of Spontaneous Speech. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 1937-1948.	1.6	13
29	Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. Immunological Investigations, 2018, 47, 135-145.	2.0	18
30	Challenges in the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders: A Case Report With a Brief Review of Literature. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961880950.	0.6	0
31	The reappearance of hemiplegic cluster headaches: A case report and review of the literature. Clinical Neurology and Neurosurgery, 2017, 158, 12-14.	1.4	1
32	Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study. Journal of Neurology, 2017, 264, 1068-1075.	3.6	25
33	How far away from having an effective treatment option for progressive multiple sclerosis are we?. Expert Opinion on Pharmacotherapy, 2017, 18, 953-955.	1.8	7
34	Avoiding misdiagnosis: cystic calcified brain metastases of uterine cervical cancer mimicking neurocysticercosis. BMJ Case Reports, 2017, 2017, bcr2016217952.	0.5	4
35	Can We Speak of Lack of Habituation in Visual Snow?. Headache, 2016, 56, 1517-1518.	3.9	6
36	Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy, 2014, 15, 1019-1027.	1.8	16

#	Article	IF	CITATIONS
37	The Incidence of Amyotrophic Lateral Sclerosis in Friuli Venezia Giulia, Italy, from 2002 to 2009: A Retrospective Population-Based Study. Neuroepidemiology, 2013, 41, 54-61.	2.3	20